292 related articles for article (PubMed ID: 19004065)
21. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
[TBL] [Abstract][Full Text] [Related]
22. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems.
Arisawa H; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(3):162-7. PubMed ID: 11963642
[TBL] [Abstract][Full Text] [Related]
23. ACR presentations support Salagen tablets as a safe and effective treatment for the dry mouth symptoms caused by Sjögren's syndrome.
Compr Ther; 1999 Jan; 25(1):53. PubMed ID: 9987593
[No Abstract] [Full Text] [Related]
24. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
[TBL] [Abstract][Full Text] [Related]
25. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
[TBL] [Abstract][Full Text] [Related]
26. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management.
Al-Hashimi I
Drugs Aging; 2005; 22(11):887-99. PubMed ID: 16323968
[TBL] [Abstract][Full Text] [Related]
27. A new medication for treatment of dry mouth in Sjögren's syndrome.
al-Hashimi I; Taylor SE
Tex Dent J; 2001 Apr; 118(3):262-6. PubMed ID: 11404944
[TBL] [Abstract][Full Text] [Related]
28. Sjogren's syndrome and pseudolymphoma.
Deutsch HJ
Ann Otol Rhinol Laryngol; 1967 Dec; 76(5):1074-84. PubMed ID: 6074240
[No Abstract] [Full Text] [Related]
29. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
[TBL] [Abstract][Full Text] [Related]
30. [Sjogren's syndrome and changes in the salivary glands].
Brands T; Schnepper E; Wannenmacher M
Dtsch Zahn Mund Kieferheilkd Zentralbl Gesamte; 1969 Oct; 53(5):226-33. PubMed ID: 5266064
[No Abstract] [Full Text] [Related]
31. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.
Akpek EK; Lindsley KB; Adyanthaya RS; Swamy R; Baer AN; McDonnell PJ
Ophthalmology; 2011 Jul; 118(7):1242-52. PubMed ID: 21459453
[TBL] [Abstract][Full Text] [Related]
32. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
[No Abstract] [Full Text] [Related]
33. Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice.
Nishimura H; Yakeishi A; Saga T; Yamaki K
Kurume Med J; 2009; 56(3-4):39-47. PubMed ID: 20505281
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of xerostomia with pilocarpine. Based on l5 years' experience and treatment of 500 patients].
Szabó G
Fogorv Sz; 1985 Mar; 78(3):65-9. PubMed ID: 3857197
[No Abstract] [Full Text] [Related]
35. Sjögren's syndrome with chronic inflammatory demyelinating polyneuropathy.
Lin WS; Hsu YD
Neurol India; 2011; 59(3):476-8. PubMed ID: 21743193
[No Abstract] [Full Text] [Related]
36. Re: Researchers make slow headway in managing dry mouth.
LeVeque F
J Natl Cancer Inst; 1997 Dec; 89(24):1894-5. PubMed ID: 9414180
[No Abstract] [Full Text] [Related]
37. Parotid calcifications in Sjogren's syndrome.
Guggenheimer J; Wiggins HE
Oral Surg Oral Med Oral Pathol; 1970 Sep; 30(3):378-9. PubMed ID: 5270891
[No Abstract] [Full Text] [Related]
38. [Primary Gougerot-Sjögren syndrome with necrotizing polymyositis: favorable effect of hydroxychloroquine].
Ponge T; Mussini JM; Ponge A; Forgeau Y; Barrier J; Cottin S; Grolleau JY
Rev Neurol (Paris); 1987; 143(2):147-8. PubMed ID: 3602794
[TBL] [Abstract][Full Text] [Related]
39. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox RI
Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
[No Abstract] [Full Text] [Related]
40. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
Nishinarita M; Hanzawa M; Iikuni N; Ota S
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
